Skip to main content
Clinical Trials/NCT00785382
NCT00785382
Completed
Phase 4

A Randomized, Placebo Controlled Trial of Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery

IWK Health Centre1 site in 1 country62 target enrollmentJanuary 2009

Overview

Phase
Phase 4
Intervention
Placebo
Conditions
Postoperative Pain
Sponsor
IWK Health Centre
Enrollment
62
Locations
1
Primary Endpoint
The primary outcome will be postoperative pain, measured by a NRS and the quality of recovery score (QoR) in the first 24h postoperative period.
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

We hypothesize that pregabalin will decrease postoperative pain, as measured by the surrogate markers postoperative pain rating scores and postoperative opioid consumption while improving the quality of recovery following breast cancer surgery compared to placebo. The primary outcome will be postoperative pain, measured by a NRS and the quality of recovery score (QoR) in the first 24h postoperative period. Do women undergoing breast cancer surgery with general anesthesia and receiving pregabalin prior to their surgery and 12 hours later have lower NRS and a greater QoR score in the first 24 hours after their surgery than those women who received placebo?

Registry
clinicaltrials.gov
Start Date
January 2009
End Date
December 2011
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ronald George

Primary Investigator, MD, FRCPC, Assistant Professor

IWK Health Centre

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesia physical status class I \& II
  • Age ¬\< 65 years
  • English-speaking
  • Unilateral breast cancer surgery without axillary node dissection (i.e. simple mastectomies and lumpectomies +/- "sentinal" node biopsy)

Exclusion Criteria

  • Known or suspected allergy, sensitivity, or contraindication to pregabalin
  • Known or suspected allergy to morphine, NSAIDs, acetaminophen or oxycodone
  • Morbid Obesity (Body Mass Index ≥ 45 kg/m2)
  • History of a seizure disorder
  • Current pre-operative therapy with pregabalin, gabapentin, or any opioid
  • Any other physical or psychiatric condition which may impair their ability to cooperate with postoperative study data collection
  • CrCl \< 60 ml/min \[CrCl = 0.85 x ((140 - age) x weight(kg)) / (72 x Cr(mg/dL)))\]

Arms & Interventions

1

Intervention: Placebo

2

Intervention: Pregabalin 150 mg

Outcomes

Primary Outcomes

The primary outcome will be postoperative pain, measured by a NRS and the quality of recovery score (QoR) in the first 24h postoperative period.

Time Frame: 24 hours

Secondary Outcomes

  • NRS / QoR - 48 hour Opioid Consumption Side effects - nausea, sedation(48 hours)

Study Sites (1)

Loading locations...

Similar Trials